Theravance Biopharma Ireland Limited, and Pfizer announced the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor that can be rapidly metabolized. The compounds in this program target validated pro-inflammatory pathways and are specifically designed to process skin-selective activity with minimal systemic exposure.
https://www.sumeetsud.com/sumeet-sud-shares-news-about-global-license-agreement/
https://www.sumeetsud.com/tag/global/
https://www.sumeetsud.com/tag/license/
https://www.sumeetsud.com/tag/pfizer/